Approved treatments for myasthenia gravis

Immunosuppressants also may be used treat MG. These therapies either inhibit or prevent activity of the immune system when it tries to fight the receptors required to transmit nerve signals to muscles.

Mestinon (pyridostigmine bromide) is an oral acetylcholinesterase inhibitor approved for the treatment of myasthenia gravis (MG). It is available in the form of conventional or extended-release tablets or syrup.

Corticosteroids such as prednisone suppress the immune system by reducing the production of antibodies, or proteins that attack or block a specific invader or other target. This results in less damage to receptors at nerve-muscle junctions, easing the symptoms of MG.

Rystiggo (rozanolixizumab-noli) is an FcRn blocker approved for adults with generalized myasthenia gravis (gMG) who have antibodies against the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK). The therapy is given via an under-the-skin (subcutaneous) infusion once weekly in six-week cycles.

Soliris (eculizumab) is a complement inhibitor approved for the treatment of adults with generalized myasthenia gravis (gMG) who are positive for antibodies against the acetylcholine receptor (AChR). It is administered via an into-the-vein (intravenous) infusion, with maintenance doses given every two weeks.

Ultomiris (ravulizumab-cwvz) is a complement inhibitor approved for the treatment of adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR). It is administered via an into-the-vein (intravenous) infusion, with maintenance doses given every eight weeks.

Vyvgart (efgartigimod alfa-fcab) is an FcRn blocker approved for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR). The therapy is given via an into-the-vein (intravenous) infusion once weekly in four-week cycles.

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) is an FcRn blocker approved for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR). It is administered via an under-the-skin (subcutaneous) injection once weekly in four-week cycles.

Zilbrysq (zilucoplan) is a complement inhibitor approved for treatment of adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR). It is administered via an under-the-skin (subcutaneous) injection once daily.

Other strategies that can be used to treat myasthenia gravis (MG) patients include intravenous immunoglobulin (IVIG) infusions, plasmapheresis, and thymectomy. These procedures broadly aim to lower the levels of MG-driving autoantibodies in the bloodstream to ease disease symptoms.